Tawanda Mandizvo graduated with a BSc in Biochemistry and Chemistry from the University of KwaZulu-Natal (UKZN), Durban, South Africa, and a BSc Honours in Medicinal Chemistry from Rhodes University, Grahamstown, South Africa, and a Master of Medical Science degree from UKZN. His Masters research focused on developing the LightForge system—a highly scalable microfluidic platform for genomic drug susceptibility interrogation of tuberculosis strains. For this work, he has been awarded a coveted medal by the Southern Africa Association for the Advancement of Science (S2A3), as well as the prestigious Canon Collins scholarship for exceptional scholars in Southern Africa.
He has recently worked on understanding the interplay between metabolism and immunity in pulmonary TB, and how pharmacological interventions targeting immunometabolism could boost protective anti-TB immunity and improve clinical outcomes.
Mandizvo represents a new demographic of young African scientists with a distinct unmistakable interest towards the pursuit of innovative ways to address global health challenges. Currently, he is exploring the potential of broadly neutralising monoclonal antibodies for HIV-1 prevention and cure.